Performance evaluation of the Abbott RealTime HCV genotype II for hepatitis C virus genotyping

Yong Hak Sohn, Sun-Young Ko, Myeong Hee Kim, Heung Bum Oh

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: The Abbott RealTime hepatitis C virus (HCV) Genotype II (Abbott Molecular Inc.) for HCV genotyping, which uses real-time PCR technology, has recently been developed. Methods: Accuracy and sensitivity of detection were assessed using the HCV RNA PHW202 performance panel (SeraCare Life Sciences). Consistency with restriction fragment mass polymorphism (RFMP) data, cross-reactivity with other viruses, and the ability to detect minor strains in mixtures of genotypes 1 and 2 were evaluated using clinical samples. Results: All performance panel viruses were correctly genotyped at levels of >500 IU/mL. Results were 100% concordant with RFMP genotypic data (66/66). However, 5% (3/66) of the samples examined displayed probable genotypic cross reactivity. No cross reactivity with other viruses was evident. Minor strains in the mixtures were not effectively distinguished, even at quantities higher than the detection limit. Conclusions: The Abbott RealTime HCV Genotype II assay was very accurate and yielded results consistent with RFMP data. Although the assay has the advantages of automation and short turnaround time, we suggest that further improvements are necessary before it is used routinely in clinical practice. Efforts are needed to decrease cross reactivity among genotypes and to improve the ability to detect minor genotypes in mixed infections.

Original languageEnglish
Pages (from-to)469-474
Number of pages6
JournalClinical Chemistry and Laboratory Medicine
Volume48
Issue number4
DOIs
Publication statusPublished - 2010 Apr 1
Externally publishedYes

Fingerprint

Viruses
Hepacivirus
Genotype
Polymorphism
Assays
Biological Science Disciplines
Automation
Coinfection
Turnaround time
Limit of Detection
Real-Time Polymerase Chain Reaction
RNA
Technology

Keywords

  • Genotype
  • Genotyping
  • HCV
  • Method evaluation
  • Real-time PCR

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Performance evaluation of the Abbott RealTime HCV genotype II for hepatitis C virus genotyping. / Sohn, Yong Hak; Ko, Sun-Young; Kim, Myeong Hee; Oh, Heung Bum.

In: Clinical Chemistry and Laboratory Medicine, Vol. 48, No. 4, 01.04.2010, p. 469-474.

Research output: Contribution to journalArticle

@article{64274ac2237f4232b1ac7410f0629326,
title = "Performance evaluation of the Abbott RealTime HCV genotype II for hepatitis C virus genotyping",
abstract = "Background: The Abbott RealTime hepatitis C virus (HCV) Genotype II (Abbott Molecular Inc.) for HCV genotyping, which uses real-time PCR technology, has recently been developed. Methods: Accuracy and sensitivity of detection were assessed using the HCV RNA PHW202 performance panel (SeraCare Life Sciences). Consistency with restriction fragment mass polymorphism (RFMP) data, cross-reactivity with other viruses, and the ability to detect minor strains in mixtures of genotypes 1 and 2 were evaluated using clinical samples. Results: All performance panel viruses were correctly genotyped at levels of >500 IU/mL. Results were 100{\%} concordant with RFMP genotypic data (66/66). However, 5{\%} (3/66) of the samples examined displayed probable genotypic cross reactivity. No cross reactivity with other viruses was evident. Minor strains in the mixtures were not effectively distinguished, even at quantities higher than the detection limit. Conclusions: The Abbott RealTime HCV Genotype II assay was very accurate and yielded results consistent with RFMP data. Although the assay has the advantages of automation and short turnaround time, we suggest that further improvements are necessary before it is used routinely in clinical practice. Efforts are needed to decrease cross reactivity among genotypes and to improve the ability to detect minor genotypes in mixed infections.",
keywords = "Genotype, Genotyping, HCV, Method evaluation, Real-time PCR",
author = "Sohn, {Yong Hak} and Sun-Young Ko and Kim, {Myeong Hee} and Oh, {Heung Bum}",
year = "2010",
month = "4",
day = "1",
doi = "10.1515/CCLM.2010.093",
language = "English",
volume = "48",
pages = "469--474",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "4",

}

TY - JOUR

T1 - Performance evaluation of the Abbott RealTime HCV genotype II for hepatitis C virus genotyping

AU - Sohn, Yong Hak

AU - Ko, Sun-Young

AU - Kim, Myeong Hee

AU - Oh, Heung Bum

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Background: The Abbott RealTime hepatitis C virus (HCV) Genotype II (Abbott Molecular Inc.) for HCV genotyping, which uses real-time PCR technology, has recently been developed. Methods: Accuracy and sensitivity of detection were assessed using the HCV RNA PHW202 performance panel (SeraCare Life Sciences). Consistency with restriction fragment mass polymorphism (RFMP) data, cross-reactivity with other viruses, and the ability to detect minor strains in mixtures of genotypes 1 and 2 were evaluated using clinical samples. Results: All performance panel viruses were correctly genotyped at levels of >500 IU/mL. Results were 100% concordant with RFMP genotypic data (66/66). However, 5% (3/66) of the samples examined displayed probable genotypic cross reactivity. No cross reactivity with other viruses was evident. Minor strains in the mixtures were not effectively distinguished, even at quantities higher than the detection limit. Conclusions: The Abbott RealTime HCV Genotype II assay was very accurate and yielded results consistent with RFMP data. Although the assay has the advantages of automation and short turnaround time, we suggest that further improvements are necessary before it is used routinely in clinical practice. Efforts are needed to decrease cross reactivity among genotypes and to improve the ability to detect minor genotypes in mixed infections.

AB - Background: The Abbott RealTime hepatitis C virus (HCV) Genotype II (Abbott Molecular Inc.) for HCV genotyping, which uses real-time PCR technology, has recently been developed. Methods: Accuracy and sensitivity of detection were assessed using the HCV RNA PHW202 performance panel (SeraCare Life Sciences). Consistency with restriction fragment mass polymorphism (RFMP) data, cross-reactivity with other viruses, and the ability to detect minor strains in mixtures of genotypes 1 and 2 were evaluated using clinical samples. Results: All performance panel viruses were correctly genotyped at levels of >500 IU/mL. Results were 100% concordant with RFMP genotypic data (66/66). However, 5% (3/66) of the samples examined displayed probable genotypic cross reactivity. No cross reactivity with other viruses was evident. Minor strains in the mixtures were not effectively distinguished, even at quantities higher than the detection limit. Conclusions: The Abbott RealTime HCV Genotype II assay was very accurate and yielded results consistent with RFMP data. Although the assay has the advantages of automation and short turnaround time, we suggest that further improvements are necessary before it is used routinely in clinical practice. Efforts are needed to decrease cross reactivity among genotypes and to improve the ability to detect minor genotypes in mixed infections.

KW - Genotype

KW - Genotyping

KW - HCV

KW - Method evaluation

KW - Real-time PCR

UR - http://www.scopus.com/inward/record.url?scp=77949870919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949870919&partnerID=8YFLogxK

U2 - 10.1515/CCLM.2010.093

DO - 10.1515/CCLM.2010.093

M3 - Article

VL - 48

SP - 469

EP - 474

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

SN - 1434-6621

IS - 4

ER -